Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.
Rieder
Florian
F
Dept. of Gastroenterology and Hepatology, NC22, Cleveland Clinic Foundation; 9500 Euclid Ave., Cleveland, OH, 44195. riederf@ccf.org.
Biancani
Piero
P
Harnett
Karen
K
Yerian
Lisa
L
Falk
Gary W
GW
D000818:Animals; D042783:Endothelial Cells / Q000502:physiology; D015154:Esophageal Motility Disorders / Q000209:etiology; D004938:Esophageal Neoplasms / Q000209:etiology*; D004941:Esophagitis / Q000209:etiology; D004943:Esophagogastric Junction / Q000503:physiopathology*; D005355:Fibrosis / Q000209:etiology; D005764:Gastroesophageal Reflux / Q000150:complications / Q000503:physiopathology*; D005769:Gastrointestinal Motility / Q000502:physiology; D006801:Humans; D018836:Inflammation Mediators / Q000494:pharmacology / Q000502:physiology*; D007375:Interleukin-1 / Q000502:physiology; D015850:Interleukin-6 / Q000502:physiology; D016209:Interleukin-8 / Q000502:physiology; D008648:Mesoderm / Q000166:cytology; D010972:Platelet Activating Factor / Q000502:physiology; D017382:Reactive Oxygen Species / Q000378:metabolism
D018836:Inflammation Mediators; D007375:Interleukin-1; D015850:Interleukin-6; D016209:Interleukin-8; D010972:Platelet Activating Factor; D017382:Reactive Oxygen Species